Agency Agrees to Review Human Stem Cell Patents
<p class="source">The New York Times</p>
<p>In their request for a re-examination, the consumer group FTCR and the Public Patent Foundation (PUBPAT) said Dr. Thomson's work did not deserve patents because three scientific papers by others and one previous patent had already laid out how to derive embryonic stem cells in various animals including mice, pigs and sheep.</p>
